Funded Project Details - FY2021
|Title:|| Hexokinase 2 and cancer therapy|
|Congressional District Code:
||Biomedical Laboratory R&D
|| July 2016 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
DESCRIPTION (provided by PI): Cancer cells are metabolically different from normal matching cells, and this is manifested by the high rate of glucose metabolism in cancer cells. Because high rate of aerobic glycolysis distinguishes cancer cells from normal cells it is exploited for the selective imaging of cancer cells in vivo through the utilization of the glucose analog fluoro-2-deoxyglucose (FDG) in positron emission tomography (PET). PET is used following injection of [18F]-FDG,...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.